Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181352 | 1.00 | SCN9A (0.46) | SCN9ACYP3A4PDE5AALOX5APFEN1 | |
| SCHEMBL31309136 | 0.95 | SCN9A (0.46) | SCN9ACYP3A4PDE5AALOX5APFEN1 | |
| SCHEMBL30214803 | 0.88 | SCN9A (0.39) | SCN9ACYP3A4PDE5A | |
| SCHEMBL30214805 | 0.88 | SCN9A (0.39) | SCN9ACYP3A4PDE5A | |
| SCHEMBL31309249 | 0.86 | SCN9A (0.46) | SCN9ACYP3A4ALOX5APFEN1CYP1A2 | |
| SCHEMBL31309258 | 0.85 | PDE5A (0.46) | SCN9APDE5AALOX5APFEN1 | |
| SCHEMBL24855405 | 0.85 | SLC2A1 (0.39) | SCN9APDE5A | |
| SCHEMBL30181299 | 0.85 | SLC2A1 (0.39) | SCN9APDE5A | |
| SCHEMBL29874759 | 0.84 | SCN9A (0.42) | SCN9A | |
| SCHEMBL24379605 | 0.84 | SCN9A (0.42) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503445-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2025-12-23 | — | — | US | disclosed |
| EP-4628490-A2 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4363406-B1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-20240383862-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-11-21 | — | — | US | disclosed |
| WO-2024141535-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | WO | disclosed |
| US-11970463-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2024-04-30 | — | — | US | disclosed |
| US-20230110122-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110122-A1 | COMPOUNDS AND THEIR USE | NLRP3, PYCARD, NLRP1 | SCN9A 2479/4885CYP3A4 1090/4885PDE5A 2893/4885 |
| US-20240383862-A1 | COMPOUNDS AND THEIR USE | NLRP3, PYCARD, NLRP1 | SCN9A 2479/4885CYP3A4 1090/4885PDE5A 2893/4885 |
| US-11970463-B2 | Compounds and their use | NLRP3, PYCARD, NLRP1 | SCN9A 2479/4885CYP3A4 1090/4885PDE5A 2893/4885 |
| US-12503445-B2 | Compounds and their use | NLRP3, PYCARD, NLRP1 | SCN9A 2479/4885CYP3A4 1090/4885PDE5A 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.